骨髓增生异常综合征中阿扎胞苷治疗外周血mRNA表达水平的预后影响：单中心分析
Prognostic impact of peripheral blood mRNA expression levels in response to azacytidine in MDS: A single-centre analysis.
作者信息
Maeda Tomoya, Matsuda Akira, Asou Chie, Okamura Daisuke, Tanae Ken, Kohri Mika, Ishikawa Maho, Takahashi Naoki, Tsukasaki Kunihiro, Kawai Nobutaka, Asou Norio, Bessho Masami
机构信息
Department of Haemato-Oncology, Saitama International Medical Centre, Saitama Medical University, Hidaka, Saitama, Japan.
Department of Haematology, Saitama Medical University Hospital, Saitama Medical University, Iruma-gun, Saitama, Japan.
出版信息
Leuk Res Rep. 2020 Dec 8;15:100231. doi: 10.1016/j.lrr.2020.100231. eCollection 2021.
To determine the impact of peripheral blood (PB) () mRNA levels in patients with primary myelodysplastic syndromes (MDS), we analysed the relationships between several clinical variables at the time of diagnosis and the haematological response of patients treated with azacytidine. We observed overall responses in 20 (63%) patients; there were no significant differences in clinical variables, including bone marrow blast counts, IPSS scores and IPSS-R risk scores, between responders and non-responders. The responders' PB mRNA levels were significantly lower than those of non-responders ( = 0.03). PB mRNA expression could be a marker for predicting the response to azacytidine in patients with MDS.
为了确定原发性骨髓增生异常综合征（MDS）患者外周血（PB）（）mRNA水平的影响，我们分析了诊断时几个临床变量与接受阿扎胞苷治疗患者的血液学反应之间的关系。我们观察到20例（63%）患者有总体反应；反应者和无反应者之间在临床变量上无显著差异，包括骨髓原始细胞计数、国际预后评分（IPSS）和修订的国际预后评分（IPSS-R）风险评分。反应者的PB mRNA水平显著低于无反应者（P = 0.03）。PB mRNA表达可能是预测MDS患者对阿扎胞苷反应的一个标志物。
Zotero 插件